Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director
Intimation of Resignation of Managing Director of the Company.04-02-2021
04-02-2021
Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Publication of Notice of Postal Ballot to Members.21-01-2021
Parmax Pharma Ltd - 540359 - Intimation Under Regulation 30 For Issuance Of Postal Ballot Notice To The Shareholders And Submission Of Postal Ballot Notice Dated 16Th January, 2021 Of The Company And E-Voting Facility.
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a copy of the Postal Ballot Notice being sent to the Shareholders of the Company pursuant to Section 108 and 110 of the Companies Act, 2013, Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for their approval. The said notice is dispatched to the Members whose names appeared in the Register of Members/ Beneficial Owners as on Tuesday, 19th January, 2021 i.e. cut-off date for the said purpose through email only. The Company has engaged the services of CDSL for the purpose of providing remote e-voting facility to the members. The voting will commence from 9:00 AM on Thursday 21st January, 2021 and end at 5:00 PM on Friday 19th February, 2021. The notice of the postal ballot is also available on our website i.e. www.parmaxpharma.com.20-01-2021
Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended December 31, 2020
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here19-01-2021
Parmax Pharma Ltd - 540359 - Outcome Of Board Meeting.
Outcome of Board Meeting dated 16th January, 202116-01-2021
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of The Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/01/2021 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on the Saturday, 16th January 2021 inter alia to consider and approve the following businesses: 1. To approve the Preferential issue, Quantum and Determination of Issue Price of Securities. 2. To appoint Registered valuer and Merchant Banker for determining the issue price. 3. Any other business with the consent of Board.09-01-2021
Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st December, 202005-01-2021
Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer04-01-2021
Parmax Pharma Ltd - 540359 - Closure of Trading Window
This is to inform you that pursuant to Company''s Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities and SEBI (Prohibition of Insider Trading) Regulations, 2015, ''Trading Window'' for dealing in securities of the Company for designated persons will remain closed with immediate effect till 48 hours after the declaration of financial results for the Quarter and nine months ended on 31st December, 2020. The date of announcement of the financial results for the Quarter and nine months ended on 31st December, 2020 shall be announced in due course.29-12-2020
Parmax Pharma Ltd - 540359 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pravina Mahasukhlal Gopani23-12-2020